Trial Results Show Significant Blood Sugar Reduction<\/p>\n
Novo Nordisk said its phase 3a PIONEER TEENS trial demonstrated a statistically significant reduction in blood sugar levels, with HbA1c declining by 0.83% compared to placebo at 26 weeks.\u00a0<\/p>\n
The study evaluated oral semaglutide in 132 children and adolescents aged 10-17 and showed a safety profile consistent with previous semaglutide trials.\u00a0<\/p>\n
“This confirms that oral semaglutide is an effective treatment option for children and adolescents with type 2 diabetes,” said Martin Holst Lange, chief scientific officer at Novo Nordisk.\u00a0<\/p>\n
The company said the trial represents the first clinical study of an oral GLP-1 receptor agonist therapy in this age group, addressing a significant unmet need.\u00a0<\/p>\n
Novo Nordisk expects to file for regulatory approval to expand the label for oral semaglutide in the U.S. and EU in the second half of the year.\u00a0<\/p>\n
Novo Nordisk Shares Edge Higher<\/p>\n
NVO Price Action: At the time of publication, Novo Nordisk shares are trading 3.66% higher at $39.93, according to data from Benzinga Pro<\/a>.<\/p>\n Image via Shutterstock<\/p>\n This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.<\/p>\n